<p>Recent decades have seen Parkinson’s disease (PD) recognized as a multisystem disorder characterized by significant neuropsychiatric disturbances. The most clinically significant of these are depression and cognitive impairment (CI), which may occur before the manifestation of motor symptoms, defining the course of illness and reducing patients’ quality of life. The high prevalence of these disorders and their impact on clinical prognosis necessitate an in-depth study of their developmental mechanisms, risk factors, and therapeutic options. The combination of depression and CI is observed on average in a third of patients with PD and is associated with more severe cognitive deficits. Neuroimaging and clinical-functional studies have confirmed the existence of common morphofunctional and neurochemical mechanisms underlying these disorders. Recent observations have indicated that depression may serve as a predictor of faster cognitive decline. Severe depressive disorders can limit the effectiveness of both antidepressant pharmacotherapy and psychotherapy, while cognitive dysfunction further reduces the effectiveness of antidepressant treatment. In this regard, comprehensive and systematic assessment of the neuropsychiatric status of patients with PD at all stages of illness and the development of multidisciplinary therapeutic strategies aimed at correcting affective and cognitive impairments are of particular importance. Timely diagnosis and correction of depressive symptoms can potentially slow the progression of cognitive deficits, while correction of cognitive impairments can increase the effectiveness of antidepressant treatment. A comprehensive approach to depression and cognitive impairment in PD should include pharmacological agents (dopaminergic agents, antidepressants) and non-pharmacological approaches in the form of cognitive behavioral therapy, motor rehabilitation, and rTMS.</p>